Controllable intein splicing and N-terminal cleavage at mesophilic temperatures by Taylor A. McNeal, Joel Weinberger, Geraldy L. S. Liman, Tia M. Ariagno, David W. Wood, Thomas J. Santangelo, Christopher W. Lennon

“…The ability of inteins to specifically rearrange peptide bonds has proven exceptionally useful in protein engineering, thus, methods to control intein activity are of considerable interest. …”
Get full text

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies by Aimee E. Mattei, Andres H. Gutierrez, Soorya Seshadri, Jacob Tivin, Matt Ardito, Amy S. Rosenberg, William D. Martin, Anne S. De Groot

“…This toolkit has evolved and now contains an array of algorithms that can be used individually and/or consecutively for immunogenicity assessment and protein engineering. Most analyses start with the advanced epitope mapping tool (EpiMatrix), then proceed to identify epitope clusters using ClustiMer, and then use a tool called JanusMatrix to define whether any of the T cell epitope clusters may generate a regulatory T cell response which may diminish or eliminate anti-drug antibody formation. …”
Get full text

Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy by Apisitt Thaiprayoon, Yodpong Chantarasorn, Worrapoj Oonanant, Anongnard Kasorn, Phoomintara Longsompurana, Satita Tapaneeyakorn, Pinpunya Riangrungroj, Fabien Loison, Andrew C. Kruse, Matthew P. DeLisa, Dujduan Waraho-Zhmayev

“…We anticipate that our strategy will be a valuable addition to the protein engineering toolkit, allowing development of Nbs or virtually any other synthetic binding protein for a wide range of applications.…”
Get full text

Essential Oils from Thymus capitatus and Thymus algeriensis as Antimicrobial Agents to Control Pathogenic and Spoilage Bacteria in Ground Meat by Asma Jayari, Ahlem Jouini, Hager Boukhris, Safa Hamrouni, Chokri Damergi, Sami Ben Hadj Ahmed, Abderrazek Maaroufi

Get full text

Role of Fcγ receptors in HER2-targeted breast cancer therapy by Hope S Rugo, Antonino Musolino, William J Gradishar, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram

“…Trastuzumab has, nonetheless, revolutionized HER2+ breast cancer treatment, and several HER2-directed mAbs have been developed using Fc glyco-engineering or Fc protein-engineering to enhance FcγR-mediated functions. …”
Get full text